본문 바로가기
KERD
논문KCI 등재

조현병 재발방지를 위한 약물치료 전략

Pharmacotherapeutic Strategies to Prevent Relapse in Schizophrenia

정영철|박염홍|김지현|신광범
대한신경정신의학회 (Korean Neuropsychiatric Association)|2018.08|신경정신의학 (JOURNAL OF THE KOREAN NEUROPSYCHIATRIC ASSOCIATION)|제57권 제3호|pp. 225-229|DOI https://doi.org/10.4306/jknpa.2018.57.3.225

2

조회

0

다운로드

5

인용

0

참고문헌

키워드

SchizophreniaComplianceLong acting injectable drugsShared decision making.
주제분류정신과학

초록

Successful treatment is very high in patients with first episode schizophrenia (FES). On the other hand, the problem is a frequent relapse often caused by non-compliance. The non-compliance rate in patients with FES is 40–60% within 1 year. The causes of non-compliance are diverse, such as poor insight, drug side effects, attitude of caregiver, social stigma, etc. Clinicians should be able to provide appropriate psychosocial intervention and long acting injectable antipsychotics (LAI) to overcome non-compliance. Recently, there is solid and accumulating evidence demonstrating superiority of LAI over oral medication in terms of reducing relapse or rehospitalization. In particular, a substantial portion (approximately 30–50%) of patients and caregivers prefer LAI to oral medication. Shared decision-making is the process that clinicians and patients/caregiver should go through in order to obtain the full benefits from LAI.

Abstract

Successful treatment is very high in patients with first episode schizophrenia (FES). On the other hand, the problem is a frequent relapse often caused by non-compliance. The non-compliance rate in patients with FES is 40–60% within 1 year. The causes of non-compliance are diverse, such as poor insight, drug side effects, attitude of caregiver, social stigma, etc. Clinicians should be able to provide appropriate psychosocial intervention and long acting injectable antipsychotics (LAI) to overcome non-compliance. Recently, there is solid and accumulating evidence demonstrating superiority of LAI over oral medication in terms of reducing relapse or rehospitalization. In particular, a substantial portion (approximately 30–50%) of patients and caregivers prefer LAI to oral medication. Shared decision-making is the process that clinicians and patients/caregiver should go through in order to obtain the full benefits from LAI.

참고문헌 (59)

  1. Systematic review of the incidence and prevalence of schizophrenia and other psychoses in England, 1950-2009, "Kirkbride JB", Department of Health Policy Research Programme, ~ (2009)
  2. 2016The survey of mental disorders in Korea, "Hong JP", Ministry of Health & Welfare, ~ (2016)
  3. Lieberman JA, "Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, doubleblind trial of olanzapine versus haloperidol", Am J Psychiatry, 160, pp.1396~1404 (2003)
  4. Merlo MC, "Risperidone, 2 mg", day vs. 4 mg, J Clin Psychiatry, pp.2002, 63[DOI]
  5. Robinson D, "Predictors of relapse following responses from a first episode of schizophrenia or schizoaffective disorder", Arch Gen Psychiatry, 56, pp.241~247 (1999)
  6. The Scottish Schizophrenia Research Group, "The Scottish first episode schizophrenia study. VIII. Five-year follow-up: clinical and psychosocial findings", Br J Psychiatry, 161, pp.496~500 (1992)
  7. Robinson DG, "Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder", Am J Psychiatry, 156, pp.544~549 (1999)
  8. Altamura AC, "Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment", Int Clin Psychopharmacol, 22, pp.249~267 (2007)
  9. Lieberman JA, "Psychobiologic correlates of treatment response in schizophrenia", Neuropsychopharmacology, 14(3 Suppl), pp.13S~21S (1996)
  10. Cahn W, "Brain volume changes in first-episode schizophrenia : a 1-year follow-up study", Arch Gen Psychiatry, 59, pp.1002~1010 (2002)
  11. Ho BC, "Progressive structural brain abnormalities and their relationship to clinical outcome : a longitudinal magnetic resonance imaging study early in schizophrenia", Arch Gen Psychiatry, 60, pp.585~594 (2003)
  12. Sun D, "Brain surface contraction mapped in first-episode schizophrenia : a longitudinal magnetic resonance imaging study", Mol Psychiatry, 14, pp.976~986 (2009)
  13. Dorph-Petersen KA, "The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation : a comparison of haloperidol and olanzapine in macaque monkeys", Neuropsychopharmacology, 30, pp.1649~1661 (2005)
  14. Ho BC, "Long-term antipsychotic treatment and brain volumes : a longitudinal study of first-episode schizophrenia", Arch Gen Psychiatry, 68, pp.128~137 (2011)
  15. Konopaske GT, "Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys", Neuropsychopharmacology, 32, pp.1216~1223 (2007)
  16. Lieberman JA, "Antipsychotic drug effects on brain morphology in first-episode psychosis", Arch Gen Psychiatry, 62, pp.361~370 (2005)
  17. Perkins DO, "Adherence to antipsychotic medications", J Clin Psychiatry, 60(Suppl 21), pp.25~30 (1999)
  18. Verdoux H, "Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects", Acta Psychiatr Scand, 102, pp.203~210 (2000)
  19. Coldham EL, "Medication adherence of individuals with a first episode of psychosis", Acta Psychiatr Scand, 106, pp.286~290 (2002)
  20. Mojtabai R, "Gaps in use of anttpsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996", Psychiatr Serv, 53, pp.337~339 (2002)
  21. Tiihonen J, "A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia", Am J Psychiatry, 168, pp.603~609 (2011)
  22. Rabinovitch M, "The influence of perceived social support on medication adherence in first-episode psychosis", Can J Psychiatry, 58, pp.59~65 (2013)
  23. Spaniel F, "The information technology aided relapse prevention programme in schizophrenia : an extension of a mirror-design follow-up", Int J Clin Pract, 62, pp.1943~1946 (2008)
  24. Komatsu H, "Effectiveness of information technology aided relapse prevention programme in schizophrenia excluding the effect of user adherence : a randomized controlled trial", Schizophr Res, 150, pp.240~244 (2013)
  25. Robinson DG, "Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder", Schizophr Res, 57, pp.209~219 (2002)
  26. Lepage M, "Is there an association between neurocognitive performance and medication adherence in first episode psychosis?", Early Interv Psychiatry, 4, pp.189~195 (2010)
  27. Baloush-Kleinman V, "Adherence to antipsychotic drug treatment in early-episode schizophrenia : a six-month naturalistic follow-up study", Schizophr Res, 130, pp.176~181 (2011)
  28. Quach PL, "Predictors of poor adherence to medication among patients with first-episode schizophrenia-spectrum disorder", Early Interv Psychiatry, 3, pp.66~74 (2009)
  29. Ko NY, "Investigation of insight formation using narrative analyses of people with schizophrenia in remission", J Nerv Ment Dis, 194, pp.124~127 (2006)
  30. Lester H, "Views of young people in early intervention services for first-episode psychosis in England", Psychiatr Serv, 62, pp.882~887 (2011)
  31. Staring AB, "Stigma moderates the associations of insight with depressed mood, low self-esteem, and low quality of life in patients with schizophrenia spectrum disorders", Schizophr Res, 115, pp.363~369 (2009)
  32. Chatterjee A, "Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never medicated schizophrenic patients", Am J Psychiatry, 152, pp.1724~1729 (1995)
  33. Curtis J, "Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis", Early Interv Psychiatry, 10, pp.267~276 (2016)
  34. Verma S, "Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis", Aust N Z J Psychiatry, 43, pp.812~817 (2009)
  35. Kampman O, "Indicators of medication compliance in first-episode psychosis", Psychiatry Res, 110, pp.39~48 (2002)
  36. Robinson DG, "Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder", Schizophr Res, 57, pp.209~219 (2002)
  37. Abhijnhan A, "Depot fluspirilene for schizophrenia", Cochrane Database Syst Rev, 24, pp.CD001718~ (2007)
  38. Leucht C, "Oral versus depot antipsychotic drugs for schizophreni--a critical systematic review and meta-analysis of randomised long-term trials", Schizophr Res, 127, pp.83~92 (2011)
  39. Tiihonen J, "Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with Schizophrenia", JAMA Psychiatry, 74, pp.686~693 (2017)
  40. Bartzokis G, "Long acting injection versus oral risperidone in first-episode schizophrenia : differential impact on white matter myelination trajectory", Schizophr Res, 132, pp.35~41 (2011)
  41. Nasrallah HA., "Triple advantages of injectable long acting second generation antipsychotics: relapse prevention, neuroprotection, and lower mortality", Schizophr Res, 197, pp.69~70 (2018)
  42. Kirschner M, "Patients’and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis", Ther Adv Psychopharmacol, 3, pp.89~99 (2013)
  43. Přikryl R, "Role of long-acting injectable second-generation antipsychotics in the treatment of first-episode schizophrenia : a clinical perspective", Schizophr Res Treatment, 2012, pp.764769~ (2012)
  44. Taylor M, "Should long-acting(depot)antipsychotics be used in early schizophrenia? A systematic review", Aust N Z J Psychiatry, 47, pp.624~630 (2012)
  45. Subotnik KL, "Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia", JAMA Psychiatry, 72, pp.822~829 (2015)
  46. Lehman AF, "Practice guideline for the treatment of patients with schizophrenia, second edition", Am J Psychiatry, 161(2 Suppl), pp.1~56 (2004)
  47. Canadian Psychiatric Association, "Clinical practice guidelines. Treatment of schizophrenia", Can J Psychiatry, 50(13 Suppl 1), pp.7S~57S (2005)
  48. Schizophrenia:core interventions in the treatment and management of schizophrenia in primary and secondary care, "National Collaborating Centre for Mental Health (UK)", British Psychological Society, ~ (2009)
  49. Moore TA, "The Texas medication algorithm project antipsychotic algorithm for schizophrenia : 2006 update", J Clin Psychiatry, 68, pp.1751~1762 (2007)
  50. Kane JM, "Clinical guideline recommendations for antipsychotic long-acting injections", Br J Psychiatry, 52, pp.S63~S67 (2009)
  51. Castle DJ, "The 2016 Royal Australian and New Zealand College of Psychiatrists guidelines for the management of schizophrenia and related disorders", Med J Aust, 206, pp.501~505 (2017)
  52. Kang G, "Attitudes of patients with schizophrenia and their caretakers toward treatment with long-acting injectable antipsychotic medication", J Korean Assoc Soc Psychiatry, 15, pp.67~73 (2010)
  53. Barnes TR, "Antipsychotic long-acting injections: prescribing practice in the UK", Br J Psychiatry, 52, pp.S37~S42 (2009)
  54. Jaeger M, "Attitudes towards long-acting depot antipsychotics:a survey of patients, relatives and psychiatrists", Psychiatry Res, 175, pp.58~62 (2010)
  55. 이융, "지역사회에 거주하는 조현병 환자와 보호자들의 장기지속형 주사제 항정신병약물에 대한 선호도 조사", 대한조현병학회지, 16(1), pp.14~24 (2013), 대한조현병학회
  56. Yeo SU, "Acceptance rate of long-acting injection after short information : a survey in patients with first-and multiple-episode psychoses and their caregivers", Early Interv Psychiatry, 11, pp.509~516 (2017)
  57. Elwyn G, "Shared decision making : a model for clinical practice", J Gen Intern Med, 27, pp.1361~1367 (2012)
  58. Dolder CR, "Antipsychotic medication adherence : is there a difference between typical and atypical agents?", Am J Psychiatry, 159, pp.103~108 (2002)
  59. Gilmer TP, "Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia", Am J Psychiatry, 161, pp.692~699 (2004)

관련 논문AI추천

장기지속형 항정신병약물의 임상 실제이규영대한신경정신의학회 · 신경정신의학2019 · 제58권 제1호Long-acting Injectable Antipsychotics in First-episode Schizophrenia이문수, 정현강대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2013 · 제11권 제1호조현병 환자에서 항정신병약물 유지치료 시 치료결과에 대한 연구나의현, 박은경, 배하현, 윤해주, 이종일대한조현병학회 · 대한조현병학회지2017 · 제20권 제2호돌파정신병과 항정신병약물 장기지속형 주사제김용식, 이규영, 정성훈, 주은정대한조현병학회 · 대한조현병학회지2023 · 제26권 제1호팔리페리돈 장기지속형주사제의 약물 순응도와 치료 효과김창윤, 김하린, 이중선, 주연호대한신경정신의학회 · 신경정신의학2015 · 제54권 제1호Factors Affecting Continuation of Aripiprazole Long-acting Injection in the Real WorldJae-Nam Bae, Jeong Seop Lee, Seri Maeng, Soyeon Chang, Won-Hyoung Kim, Yangsik Kim대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2025 · 제23권 제2호

이 간행물의 다른 논문 (8건)

조현병과 조기 정신증 치료하기이헌정pp. 209-209정신증고위험군의 임상적 특성 및 진단안석균pp. 210-224치료 저항성 조현병의 이해와 치료김의태pp. 230-234조현병 환자를 위한 정신사회적 중재김성완pp. 235-243양극성장애 환자용 한국어판 기분 기록 스마트폰어플리케이션의 개발 및 임상적 적용윤운, 이중선, 김창윤, 이세정, 주연호, 전명욱, 송가영pp. 244-251
원문 보기